Trial Profile

A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SVN53-67-M57-KLH peptide vaccine (Primary) ; Montanide ISA-51; Sargramostim; Temozolomide; Temozolomide
Indications Glioblastoma; Gliosarcoma
Focus Proof of concept; Therapeutic Use

Most Recent Events

09 Jan 2024 According to a MimiVax Media Release, new investments to support clinical development of SurVaxM in glioblastoma was catalyzed by positive results from Phase 2a study of SurVaxM in newly diagnosed glioblastoma.
15 Dec 2022 Results published in the MimiVax Media Release
15 Dec 2022 Results published in the Journal of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com